You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

CLINICAL TRIALS PROFILE FOR MIRTAZAPINE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for mirtazapine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00021528 ↗ Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Completed National Institute of Mental Health (NIMH) Phase 4 2001-07-01 STAR*D focuses on non-psychotic major depressive disorder in adults who are seen in outpatient settings. The primary purpose of this research study is to determine which treatments work best if the first treatment with medication does not produce an acceptable response. Participants will first receive citalopram, an SSRI medication; if symptoms remain after 8-12 weeks of treatment, up to four other levels of treatment will be offered, including cognitive therapy and other medications. There are no placebo treatments. Some patients may require a combination of two or more treatments to obtain full benefit. Participation could last from 15 to 27 months and involve up to 30 clinic visits. Participants will be interviewed by telephone throughout the study about their symptoms, daily functioning, treatment side effects, use of the health care system, and satisfaction with treatment. There will be a one-year follow up for participants once their depression has been successfully treated
NCT00080158 ↗ Treatment of Adolescent Suicide Attempters (TASA) Completed National Institute of Mental Health (NIMH) Phase 2/Phase 3 2004-03-01 The purpose of this study is to compare the effects of three types of treatments for depressed teenagers who have attempted suicide.
NCT00080158 ↗ Treatment of Adolescent Suicide Attempters (TASA) Completed New York State Psychiatric Institute Phase 2/Phase 3 2004-03-01 The purpose of this study is to compare the effects of three types of treatments for depressed teenagers who have attempted suicide.
NCT00108498 ↗ New Pharmacological Treatment for Obstructive Sleep Apnea Completed US Department of Veterans Affairs Phase 1 2003-10-01 This study will determine if mirtazapine, a unique antidepressant that does not disturb sleep, will improve obstructive sleep apnea (OSA). The design is randomized, crossover, double blind, and placebo controlled. On two consecutive nights of one week, the patients receive either 30 mg mirtazapine or placebo at bedtime. The following week, the alternative medication is administered. The patients have known mild to moderate sleep apnea. The endpoints of the study are the apnea + hypopnea index (AHI), sleep quality, and the degree of arterial oxygen desaturation.
NCT00108498 ↗ New Pharmacological Treatment for Obstructive Sleep Apnea Completed VA Office of Research and Development Phase 1 2003-10-01 This study will determine if mirtazapine, a unique antidepressant that does not disturb sleep, will improve obstructive sleep apnea (OSA). The design is randomized, crossover, double blind, and placebo controlled. On two consecutive nights of one week, the patients receive either 30 mg mirtazapine or placebo at bedtime. The following week, the alternative medication is administered. The patients have known mild to moderate sleep apnea. The endpoints of the study are the apnea + hypopnea index (AHI), sleep quality, and the degree of arterial oxygen desaturation.
NCT00150839 ↗ Hippocampal Volume in Young Patients With Major Depression Before and After Combined Antidepressive Therapy Completed University of Erlangen-Nürnberg Phase 4 2006-03-01 The proposed study is a randomized, placebo-controlled, double-blind trial to evaluate the safety and efficacy of antidepressant combination for the treatment of depression. Depressive disorder is one of the most common human diseases with a high burden for every patient, her/his family, health care system and society as a whole. Actual treatment concepts of depressive disorders include pharmacologic, biologic (e.g. electroconvulsive therapy, light therapy) and psychologic therapy. Even though effective therapeutic options are at hand, therapy needs time. It is often not possible to reach full remission of the disease and 10-25% of patients suffering from depression are regarded as "treatment-resistant". In treatment resistant depression, the use of a combination of antidepressive drugs is considered safe and effective. However, at present no data exist concerning the use of drug combination as primary therapeutic option. The aim of the study is to examine the hypothesis, that significantly more patients achieve full remission of depressive symptoms when treated with the combination of two antidepressants and as a secondary hypothesis, that patients receiving a drug combination will achieve remission faster than patients treated with monotherapy. To test these hypotheses, a two group parallel design is used comparing the efficacy and safety of mirtazapine in combination with venlafaxine or placebo.
NCT00150839 ↗ Hippocampal Volume in Young Patients With Major Depression Before and After Combined Antidepressive Therapy Completed University of Erlangen-Nürnberg Medical School Phase 4 2006-03-01 The proposed study is a randomized, placebo-controlled, double-blind trial to evaluate the safety and efficacy of antidepressant combination for the treatment of depression. Depressive disorder is one of the most common human diseases with a high burden for every patient, her/his family, health care system and society as a whole. Actual treatment concepts of depressive disorders include pharmacologic, biologic (e.g. electroconvulsive therapy, light therapy) and psychologic therapy. Even though effective therapeutic options are at hand, therapy needs time. It is often not possible to reach full remission of the disease and 10-25% of patients suffering from depression are regarded as "treatment-resistant". In treatment resistant depression, the use of a combination of antidepressive drugs is considered safe and effective. However, at present no data exist concerning the use of drug combination as primary therapeutic option. The aim of the study is to examine the hypothesis, that significantly more patients achieve full remission of depressive symptoms when treated with the combination of two antidepressants and as a secondary hypothesis, that patients receiving a drug combination will achieve remission faster than patients treated with monotherapy. To test these hypotheses, a two group parallel design is used comparing the efficacy and safety of mirtazapine in combination with venlafaxine or placebo.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for mirtazapine

Condition Name

Condition Name for mirtazapine
Intervention Trials
Depression 14
Major Depressive Disorder 12
Healthy 6
Anorexia 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for mirtazapine
Intervention Trials
Depression 34
Depressive Disorder 27
Depressive Disorder, Major 20
Disease 15
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for mirtazapine

Trials by Country

Trials by Country for mirtazapine
Location Trials
United States 111
China 12
Germany 6
Egypt 5
Pakistan 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for mirtazapine
Location Trials
Texas 9
Pennsylvania 8
North Carolina 8
New York 8
California 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for mirtazapine

Clinical Trial Phase

Clinical Trial Phase for mirtazapine
Clinical Trial Phase Trials
Phase 4 26
Phase 3 17
Phase 2/Phase 3 3
[disabled in preview] 49
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for mirtazapine
Clinical Trial Phase Trials
Completed 57
Recruiting 11
Unknown status 11
[disabled in preview] 20
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for mirtazapine

Sponsor Name

Sponsor Name for mirtazapine
Sponsor Trials
National Institute on Drug Abuse (NIDA) 5
National Institute of Mental Health (NIMH) 5
Ain Shams University 5
[disabled in preview] 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for mirtazapine
Sponsor Trials
Other 137
Industry 19
NIH 15
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.